HSDT
Solana·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 4
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
Price Hits New Low
Price Hits 52-week Low
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HSDT
Solana Company
A leading neurotech company in the medical device field that focused on neurologic deficits using non-implantable platform technologies
Healthcare Equipment and Supplies
03/13/2014
04/11/2018
NASDAQ Stock Exchange
21
12-31
Common stock
642 Newtown Yardley Road, Suite 100, Newtown, PA 18940
--
Solana Company was incorporated in Delaware on March 13, 2014. The company is a neurotechnology company focused on neurohealth. The purpose of the company is to develop, license or acquire non-implantable technologies aimed at alleviating symptoms of neurological diseases or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PONS), is an innovative non-implantable medical device, including a controller and a mouthpiece, that delivers gentle electrical stimulation to the surface of the tongue to treat gait defects and chronic balance defects.
Company Financials
EPS
HSDT has released its 2025 Q3 earnings. EPS was reported at -32.89, versus the expected -50.5, beating expectations. The chart below visualizes how HSDT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HSDT has released its 2025 Q3 earnings report, with revenue of 697.00K, reflecting a YoY change of 1266.67%, and net profit of -352.77M, showing a YoY change of -9470.48%. The Sankey diagram below clearly presents HSDT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
